Caribou Biosciences, Inc. (CRBU)
0.4487
+0.04
(+8.83%)
USD |
NASDAQ |
Nov 06, 16:00
0.4423
-0.01
(-1.43%)
After-Hours: 20:00
Caribou Biosciences Total Liabilities (Quarterly) : 46.39M for Sept. 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 46.39M |
| June 30, 2026 | 44.67M |
| March 31, 2026 | 46.98M |
| December 31, 2025 | 57.46M |
| September 30, 2025 | 53.14M |
| June 30, 2025 | 54.77M |
| March 31, 2025 | 56.43M |
| December 31, 2024 | 67.90M |
| September 30, 2024 | 63.13M |
| June 30, 2024 | 62.47M |
| March 31, 2024 | 63.54M |
| December 31, 2023 | 72.57M |
| Date | Value |
|---|---|
| September 30, 2023 | 59.25M |
| June 30, 2023 | 80.19M |
| March 31, 2023 | 69.19M |
| December 31, 2022 | 83.40M |
| September 30, 2022 | 74.71M |
| June 30, 2022 | 73.48M |
| March 31, 2022 | 74.20M |
| December 31, 2021 | 57.38M |
| September 30, 2021 | 57.56M |
| June 30, 2021 | 206.09M |
| March 31, 2021 | 206.14M |
| December 31, 2020 | 61.97M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Anavex Life Sciences Corp. | 7.692M |
| Vaxcyte, Inc. | 499.92M |
| Foghorn Therapeutics, Inc. | 284.43M |
| Bolt Biotherapeutics, Inc. | 27.70M |
| Connect Biopharma Holdings Ltd. | 16.61M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 123.03M |
| Shareholders Equity (Quarterly) | 76.63M |
| Debt to Equity Ratio | 0.3437 |
| Current Ratio | 4.968 |
| Net Debt Paydown Yield | -0.07% |